🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Justin P.O. Lindemann

AstraZeneca (Netherlands)

ORCID: 0000-0003-1531-9754

Also affiliated with AstraZeneca (Singapore)

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer”.

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3953

N/A

3.2DataRank · unranked

108 citations

Kenji Tamura, Mafalda Oliveira, Eva Ciruelos, Ingrid A. Mayer, Marie‐Paule Sablin +23 more

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

npj Breast Cancer(2021)10.1038/s41523-021-00251-7

N/A

1.4DataRank · unranked

36 citations

Gerald Batist, Funda Meric‐Bernstam, Peter Kabos, Iben Spanggaard, Aňa Lluch +22 more

Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection

Molecular Oncology(2021)10.1002/1878-0261.13150

N/A

0DataRank · unranked

21 citations

Emily M. Dolce, Elizabeth P. Darga, Kevin Hu, Chia‐Jen Liu, Jackie Pierce +27 more